Aura Biosciences (NASDAQ:AURA - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Aura Biosciences to post earnings of ($0.43) per share for the quarter.
Aura Biosciences Price Performance
AURA traded up $0.08 on Friday, reaching $7.50. 282,589 shares of the stock were exchanged, compared to its average volume of 169,605. The company's 50-day moving average price is $7.66 and its 200 day moving average price is $8.65. The firm has a market capitalization of $374.63 million, a PE ratio of -4.34 and a beta of 0.30. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38.
Insider Buying and Selling
In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 23,045 shares of company stock valued at $177,242 over the last ninety days. Company insiders own 5.40% of the company's stock.
Analysts Set New Price Targets
Separately, Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Aura Biosciences has an average rating of "Buy" and a consensus price target of $23.00.
Read Our Latest Stock Analysis on AURA
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Articles
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
